From the original notion of monoclonal antibodies as “magic bullets” right through to the latest generation of COVID-19 vaccines, stem cell therapies and exosomes, cell line development is experiencing a rapid expansion in both scope and output of novel biotherapeutics. Clonality, and the gathering of quality evidence, has been central to cell line development for the last decade, and with it, driving the rise of high-caliber seeding and imaging technologies.
In this informative webinar, market leader Solentim will introduce two new products, an instrument named ICON™, that is designed to empower laboratories to make better decisions faster, and an over-arching software platform called STUDIUS™.
Learn about how these two new products work to provide a new data-driven workflow for the development of modern cell-based therapies.
Participants will be hearing from Solentim’s R&D and biology groups alongside cell line development experts in this first insight into Solentim’s new products.
Register for this webinar to view the presentation, with the opportunity to ask the development team about the capabilities of these new systems.
To hear from the developers of the technologies as they present their new data-rich workflow Register Here
Duncan Borthwick, PhD, Global Marketing Manager, Solentim Ltd.
Duncan Borthwick has a PhD from the University of Edinburgh and University of North Carolina, Chapel Hill. Since hanging up his lab coat 20+ years ago, Duncan has worked in the development of novel instrumentation and products. He heads the Product Management group at Solentim, working closely with the R&D, biology and commercial teams to define the next set of products to support the cell therapy community.Message Presenter
Mark Stockdale, Amalgamator of Business and Biology, Galvanize Bio
Mark Stockdale is a keen technology consultant. He started his career at Pfizer, and has also worked as a Group Leader at Horizon Discovery Ltd, a scientist within Lonza Biologics, and at Cyclacel Ltd. With over 15 years of professional experience in cell line development and drug discovery, his passion is to bring new technologies to bear on unmet needs and provide great insight into the future technology requirements in stable cell line development.Message Presenter
Who Should Attend?
Senior professionals in biotech, biopharma and at CDMOs, including:
- Cell Line Development Scientists
- Head of Cell Line Development
- Technology Development Scientists
- Antibody Development companies
What You Will Learn
- How data is driving a new workflow for cell line development
- Transparency of clone selection and decision-making during cell line development
- Integration of automation and software in biotherapeutics
- Be the first to learn about two major new products from Solentim
Solentim is the trusted global leader for solutions to create, isolate, and characterize the highest value cells for the development of new biological medicines, including cell and gene therapies, monoclonal antibodies, vaccines and stem cells. For our customers, which include most of the world’s leading biotherapeutics companies, we are the partner of choice for facilitating the highest level of assurance in cell line development for therapeutic protein and viral vector production. Our portfolio of proven and innovative technologies, combined with our unparalleled experience, ensures our customers achieve accelerated Master Cell Bank development and are confidently prepared for regulatory review.